No association between opioids, breast cancer recurrence
the ONA take:
There is no clinically relevant evidence of an association between opioid prescriptions and breast cancer recurrence, a new study published online ahead of print in the journal Cancer has shown.
Because opioids may affect immune function, researchers sought to determine whether postdiagnosis opioid use is associated with breast cancer recurrence. For the retrospective analysis, researchers identified 34,188 patients with incident, early stage breast cancer who were diagnosed between 1996 and 2008 in Denmark.
Results showed that there was no association between ever-use of opioids and breast cancer recurrence. When researchers adjusted for opioid type, strength, duration of use, and cumulative dose, there was still no association.
Researchers found that breast cancer recurrence rates were lower among users of strongly immunosuppressive opioids, but they note that bias could have been a contributing factor.
The findings suggest that opioids, which are frequently use to manage painassociated with comorbid conditions during cancer survivorship, do not increase the risk for developing breast cancer recurrence.
There is no clinically relevant evidence of an association between opioid prescriptions and breast cancer recurrence.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|